New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
Janelle J Juul, Caitlin F Mullins, William J Peppard, Angela M Huang Department of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA Abstract: Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patie...
Saved in:
Main Authors: | Juul JJ (Author), Mullins CF (Author), Peppard WJ (Author), Huang AM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
by: Leuthner KD, et al.
Published: (2016) -
Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience
by: Sara Maria Scarano, et al.
Published: (2024) -
Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
by: Pedro Luis Gonzalez, et al.
Published: (2018) -
Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017) -
Acute bacterial skin and skin structure infections: current perspective
by: Megha Shah, et al.
Published: (2011)